Donald F. Weaver
RSC Med. Chem., 2023,14, 1645-1661
Abstract
Decades of research have yet to identify a disease modifying drug for Alzheimer's disease. This review provides an evaluation of the leading twelve druggable targets (microglial and cytokine), addressing the role of neuroinflammation in Alzheimer's.
Yaojun Ju, Yichen Yan, Xinhui Wang, Shan Li, Jialei Wang, Zixiao Wang, Yuling Dong and Junping Wang
Food Funct., 2025,16, 9519-9532
Abstract
This study investigated the therapeutic potential and mechanisms of Acer truncatum Bunge seed oil (ATSO) against cuprizone-induced white matter injury and cognitive decline.
R. S. K. Vijayan, Matthew M. Hamilton, Dana E. Pfaffinger, Fernando G. Alvarez, Naphtali J. Reyna, Jennifer P. Bardenhagen, Hannah Shepard, Christian Rodriguez, Sunil Goodwani, Yaima Lightfoot, Klaus Maskos, Sven Johannsson, Georg Kempf, Quanyun Alan Xu, Lars Neumann, Yongying Jiang, Mary Geck Do, Philip Jones, Richard T. Lewis, William J. Ray and Jason B. Cross
RSC Med. Chem., 2025,16, 5341-5358
From themed collection:
Kinases
Abstract
Parallel virtual screening and structure-guided optimization enable discovery of novel allosteric RIPK1 inhibitors.
Ji-xiang Liu, Ri-song Na, Lian-juan Yang, Xu-ri Huang and Xi Zhao
Phys. Chem. Chem. Phys., 2023,25, 31418-31430
Abstract
Six small molecules from virtual screening hits may treat neurodegenerative diseases and SARS-CoV-2 by inhibiting RIPK1.
Zechen Jin, Yang Dai, Yinchun Ji, Xia Peng, Wenhu Duan, Jing Ai and Hefeng Zhang
RSC Med. Chem., 2024,15, 2514-2526
Abstract
This study reported a series of 6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole derivatives with potent RIPK1 inhibitory activity and anti-necroptotic activity in both human and mouse cellular assays.